Mycoplasma (MG, MS)

Mycoplasma infections in poultry represent some of the most significant respiratory diseases affecting chickens, turkeys, and other domestic fowl worldwide. The two most important species causing disease are Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), each producing distinct clinical syndromes while sharing many epidemiological features. These tiny bacteria lack a cell wall, which makes them resistant to many common antibiotics while also making them fragile in the environment. Mycoplasma infections have profound economic impacts on both commercial operations and backyard flocks through reduced growth rates, decreased egg production, increased medication costs, and trade restrictions on infected stock.

Mycoplasma gallisepticum primarily causes chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys. The organism colonizes the respiratory epithelium, causing inflammation of the trachea, air sacs, and sinuses that leads to characteristic respiratory signs including sneezing, nasal discharge, and breathing difficulties. In laying hens, MG infection can cause significant drops in egg production that may persist for extended periods. The disease is particularly problematic because infected birds often become lifelong carriers, continuously shedding the organism and serving as sources of infection for susceptible flockmates and their offspring through egg transmission.

Mycoplasma synoviae, while also capable of causing respiratory disease, is particularly notable for its ability to cause infectious synovitis, an inflammation of the joints and tendon sheaths. Affected birds develop swelling of the hock joints, foot pads, and other synovial structures, leading to lameness and reluctance to move. The respiratory form of MS infection may be milder than MG but can cause similar air sac lesions and decreased production. Like MG, MS-infected birds become chronic carriers that can transmit the infection both horizontally to flockmates and vertically through contaminated eggs.

Treatment of mycoplasma infections with appropriate antibiotics can reduce clinical signs and disease severity but does not eliminate the carrier state. Infected birds remain positive for life and continue to pose a risk to susceptible birds. Prevention through biosecurity measures, testing and removal of positive birds, and maintaining closed flocks from mycoplasma-free sources represents the most effective long-term approach to controlling these diseases. Vaccination is available for some species and situations but does not prevent infection or carrier status. Working with an avian veterinarian to develop appropriate testing, treatment, and prevention strategies is essential for managing mycoplasma in poultry flocks.

Mycoplasma gallisepticum and Mycoplasma synoviae are the primary causative agents of mycoplasma disease in poultry. These organisms belong to the class Mollicutes and are characterized by their extremely small size, lack of a cell wall, and fastidious growth requirements. The absence of a cell wall renders them naturally resistant to beta-lactam antibiotics such as penicillin but also makes them sensitive to drying, detergents, and environmental extremes. Multiple strains of both MG and MS exist with varying degrees of virulence, and new variants continue to emerge that may differ in their disease-causing potential.

Horizontal transmission between birds is the primary route of spread for mycoplasma infections within and between flocks. Direct contact with infected birds or their respiratory secretions represents the most efficient transmission route. Aerosol spread can occur over short distances, particularly in enclosed housing with poor ventilation. Contaminated dust, feathers, and equipment can serve as mechanical vectors, though the organisms survive poorly outside the host. Introduction of infected birds, whether through purchase of carrier stock or exposure to infected wild birds, represents a major risk factor for previously clean flocks.

Vertical transmission from infected hens to their offspring through contaminated eggs is a critically important aspect of mycoplasma epidemiology. The organisms can penetrate the eggshell and infect the developing embryo or colonize the chick during hatching. Not all eggs from infected hens will contain mycoplasma, with transmission rates varying based on the stage of infection and other factors. However, even low rates of egg transmission are sufficient to maintain infection in successive generations and make eradication from infected breeding stock extremely difficult without depopulation.

Environmental and management factors significantly influence the likelihood and severity of mycoplasma infection. Stress from overcrowding, poor ventilation, temperature extremes, or inadequate nutrition increases susceptibility to infection and worsens clinical disease. Concurrent infections with viral respiratory pathogens such as Newcastle disease virus or infectious bronchitis virus dramatically increase the severity of mycoplasma disease. Ammonia buildup from poor litter management damages respiratory epithelium and predisposes birds to infection. Multi-age operations where older birds continuously expose younger birds perpetuate infection within a site.

The pathogenesis of mycoplasma infection involves attachment of the organisms to respiratory epithelial cells, followed by colonization and inflammation. The mycoplasmas possess specialized attachment proteins that bind to receptors on host cells, allowing them to resist clearance by respiratory mucus flow. Once established, they induce local immune responses that cause much of the tissue damage and clinical signs. The organisms can also spread from the respiratory tract to joints, reproductive organs, and other sites in the body. Chronic infection persists despite immune responses because the organisms can undergo antigenic variation and evade immune recognition.

Early warning signs of mycoplasma infection are often subtle and can easily be attributed to other causes or overlooked entirely. Birds may show slightly decreased activity levels or mild changes in vocalization before obvious respiratory signs develop. A minor decrease in feed consumption or water intake may precede clinical illness by several days. In laying flocks, a slight drop in egg production may be the first indication of a developing problem. Because mycoplasma infections often develop slowly and birds instinctively mask illness, early detection requires close observation and familiarity with normal flock behavior. Regular handling of individual birds helps identify problems before they spread throughout the flock.

Respiratory signs associated with Mycoplasma gallisepticum infection constitute the most commonly recognized presentation of the disease. Affected birds develop nasal discharge that may initially be clear but often becomes thickened and turbid as the infection progresses. Sneezing, head shaking, and wiping the beak on feathers or objects are frequently observed. Swelling of the infraorbital sinuses below the eyes produces a characteristic facial appearance with bulging tissue around the eyes. Tracheal rales and abnormal breathing sounds may be audible, especially at night when birds are quiet. Open-mouth breathing indicates severe respiratory compromise and warrants immediate attention.

Behavioral changes in mycoplasma-infected birds reflect general illness and respiratory distress. Birds become progressively less active, spending more time sitting with eyes closed and feathers ruffled. Social interactions decrease as affected birds withdraw from normal flock activities. Appetite declines, and birds may congregate near feeders without eating. Decreased preening leads to unkempt feather appearance. Laying hens may reduce or cease laying, and males may show decreased breeding activity. These nonspecific signs often precede or accompany the more specific respiratory symptoms.

Mycoplasma synoviae infection frequently manifests with joint involvement that distinguishes it from pure respiratory disease. Swelling of the hock joints is particularly common and may be the most obvious clinical sign. Affected birds show stiff, reluctant movement and may prefer to sit rather than walk or stand. Foot pad swelling (bumblefoot-like lesions) can occur. The keel bone may develop breast blisters from pressure as birds spend more time lying down. Some birds develop pale combs indicating anemia associated with chronic infection. Lameness may be the presenting complaint even when respiratory involvement is also present.

Progression of symptoms varies depending on the mycoplasma species involved, strain virulence, concurrent infections, and management factors. Simple mycoplasma infections may remain relatively mild for extended periods, while complicated cases involving secondary bacterial or viral pathogens can progress rapidly to severe disease. Respiratory signs may wax and wane with environmental conditions and stress levels. Joint involvement tends to be progressive without treatment, with chronic cases developing permanent damage. Production losses typically worsen as the infection becomes established throughout the flock.

Emergency symptoms requiring immediate veterinary attention include severe respiratory distress with open-mouth breathing, complete inability to walk or stand, extreme lethargy or unresponsiveness, and high mortality rates within the flock. Birds showing signs of secondary bacterial infection such as swollen heads, conjunctivitis, or sudden death should receive urgent evaluation. Any rapid increase in clinical signs or mortality warrants immediate investigation to identify the cause and implement appropriate treatment. Young birds and recently stressed flocks are particularly vulnerable to rapid disease progression.

Initial examination for suspected mycoplasma infection begins with thorough clinical evaluation and history taking. Veterinarians assess the pattern and progression of clinical signs, the ages of affected birds, and the distribution of illness within the flock. Information about bird sources, vaccination history, previous disease problems, and management practices helps assess the likelihood of mycoplasma versus other potential diagnoses. Physical examination focuses on respiratory signs, joint swelling, and general condition. Auscultation of the respiratory tract may reveal rales or abnormal breathing sounds. Palpation of joints assesses swelling and pain response.

Laboratory testing is essential for confirming mycoplasma infection and identifying the specific species involved. Serological testing using ELISA or rapid plate agglutination can detect antibodies to MG and MS in blood samples. However, serology has limitations including cross-reactions, delayed antibody development, and inability to distinguish current from past infection. Direct detection methods provide more definitive diagnosis. PCR testing of tracheal or choanal swabs detects mycoplasma DNA with high sensitivity and specificity. Culture of the organisms remains the gold standard but requires specialized media, expertise, and several weeks for results.

Post-mortem examination of affected or deceased birds provides valuable diagnostic information. Characteristic findings include thickened, cloudy air sacs often containing caseous exudate, tracheitis with mucoid or caseous material, and sinusitis with accumulated thick secretions. MS infection may show synovitis with increased joint fluid and inflammatory changes in tendon sheaths. Secondary bacterial infections often contribute additional lesions including fibrinous pericarditis, perihepatitis, and peritonitis. Tissue samples can be collected for culture, PCR testing, or histopathological examination to confirm diagnosis.

Differential diagnosis for mycoplasma infection includes numerous other respiratory and musculoskeletal conditions. Infectious bronchitis, Newcastle disease, infectious laryngotracheitis, and other viral respiratory diseases can produce similar respiratory signs. Ornithobacterium rhinotracheale and Avibacterium paragallinarum (infectious coryza) cause bacterial respiratory disease that may mimic mycoplasma. Bacterial arthritis from Staphylococcus or Streptococcus species can produce joint swelling resembling MS synovitis. Viral arthritis from reovirus is another consideration. Laboratory testing is usually necessary to definitively distinguish between these possibilities and identify concurrent infections that may be complicating the clinical picture.

Antibiotic therapy represents the primary treatment approach for clinical mycoplasma infections in poultry. Because mycoplasmas lack a cell wall, antibiotics that target cell wall synthesis (beta-lactams) are ineffective. Effective drug classes include macrolides (tylosin, tilmicosin, erythromycin), tetracyclines (chlortetracycline, oxytetracycline, doxycycline), fluoroquinolones (enrofloxacin), and pleuromutilins (tiamulin). Drug selection depends on the specific mycoplasma species, suspected antimicrobial susceptibility patterns, withdrawal requirements, and regulatory restrictions. Veterinary guidance is essential for selecting appropriate drugs and dosing regimens.

Medication administration in poultry typically occurs through drinking water or feed. Water medication provides relatively rapid drug delivery and can be adjusted based on flock response. Therapeutic drug concentrations must be achieved and maintained throughout the treatment period for maximum efficacy. Treatment duration varies but typically ranges from five to seven days or longer for severe cases. Feed medication allows more consistent dosing but requires adequate feed consumption by sick birds. Injectable preparations are available for individual bird treatment but are impractical for flock-wide therapy in most situations.

Surgical intervention has limited application in treating mycoplasma infections, though specific procedures may occasionally be beneficial. Aspiration of distended sinuses or joints can provide temporary relief and allow collection of samples for diagnosis and culture. Flushing of affected sinuses with saline or antibiotic solutions has been attempted with variable success. These procedures require veterinary expertise and are generally reserved for valuable individual birds rather than flock-level treatment. They address symptoms but do not eliminate the underlying infection.

Supportive care measures complement antibiotic therapy and improve treatment outcomes. Reducing environmental stressors such as overcrowding, poor ventilation, and ammonia buildup supports recovery. Optimizing nutrition and ensuring adequate water consumption helps birds maintain condition during illness. Supplemental vitamins, particularly vitamin A, support respiratory epithelium health. Managing concurrent diseases and preventing secondary bacterial infections improves overall response to treatment. Isolating severely affected birds reduces stress and allows more intensive individual care.

Alternative and complementary approaches to managing mycoplasma in poultry have been explored, though scientific evidence for most remains limited. Acidified drinking water may provide some benefit by improving gut health and reducing pathogen growth. Probiotics and prebiotics have been investigated for their potential to support immune function and competitive exclusion. Essential oils and herbal preparations with antimicrobial properties have shown activity against mycoplasmas in laboratory studies, but field efficacy is not well established. These approaches should complement rather than replace appropriate antibiotic therapy when indicated.

Treatment decisions for mycoplasma-infected flocks must consider several factors beyond immediate clinical response. Antibiotic therapy reduces clinical signs and production losses but does not eliminate the carrier state. Treated birds remain infected and can transmit the organism to susceptible birds. Withdrawal times must be observed before eggs or meat from treated birds enter the food supply. For breeding stock, the implications of maintaining positive birds versus depopulation must be weighed. Veterinary consultation helps develop treatment strategies that address both immediate clinical needs and long-term flock health goals.

Recovery from acute mycoplasma infection typically occurs over one to three weeks with appropriate antibiotic treatment and supportive care. Clinical signs of respiratory disease generally begin improving within a few days of starting effective antibiotic therapy. Joint swelling associated with MS infection may take longer to resolve and may leave permanent damage in severe or chronic cases. Production parameters including egg production and growth rates may take several weeks to return to pre-infection levels, and some permanent effects on performance may persist. Individual bird recovery varies considerably based on disease severity and concurrent infections.

Post-treatment care focuses on optimizing conditions for continued recovery while preventing relapse or spread to other birds. Environmental management should maintain good air quality, appropriate temperature, and low stress conditions. Nutrition should support recovery with adequate protein, vitamins, and minerals. Monitoring for signs of relapse or secondary infection should continue for several weeks after treatment completion. Repeated antibiotic treatment may be necessary if signs recur, though this raises concerns about antimicrobial resistance development.

Prognosis for individual birds and flocks depends on multiple factors including the mycoplasma species and strain involved, presence of concurrent infections, treatment effectiveness, and management conditions. Birds with uncomplicated MG respiratory disease often make good clinical recoveries with appropriate treatment. MS-associated joint disease may leave permanent lameness if chronic inflammation damages joint structures. Concurrent viral infections significantly worsen prognosis and may result in higher mortality. Flocks with good management and low stress generally have better outcomes than those with ongoing environmental challenges.

Long-term outlook for mycoplasma-infected flocks must account for the permanent carrier status of recovered birds. Clinical recovery does not equate to elimination of infection, and all recovered birds should be considered lifelong carriers capable of transmitting the organism. This carrier status has significant implications for breeding operations, as vertical transmission can perpetuate infection in offspring. Flock-level decisions about maintaining infected birds versus depopulation depend on the operation's goals, the value of the stock, and the feasibility of managing a positive flock. Working with avian veterinarians to develop long-term management strategies helps optimize outcomes while minimizing ongoing disease impact.

Environmental prevention measures form the foundation of mycoplasma control in poultry operations. Proper housing design with adequate ventilation reduces the concentration of airborne pathogens and prevents the buildup of ammonia that damages respiratory defenses. All-in, all-out production systems prevent continuous cycling of infection between age groups. Thorough cleaning and disinfection between flocks reduces environmental contamination, and mycoplasmas are relatively susceptible to common disinfectants due to their lack of a cell wall. Maintaining appropriate stocking densities reduces stress and direct contact transmission. Pest control programs eliminate potential mechanical vectors.

Biosecurity and quarantine protocols are essential for preventing mycoplasma introduction into clean flocks. The most effective strategy is maintaining a closed flock with no introduction of outside birds. When additions are necessary, source birds should come from certified mycoplasma-free flocks with documented testing history. Quarantine of new birds for at least three to four weeks with testing before introduction provides additional protection. Strict traffic control limiting access to the premises reduces the risk of mechanical introduction. Dedicated clothing, footwear, and equipment for each flock prevents cross-contamination.

Nutritional management supports immune function and resistance to mycoplasma infection. Complete, balanced diets meeting all nutritional requirements maintain optimal immune system function. Adequate vitamin A levels are particularly important for respiratory epithelium integrity. Avoiding nutritional stress from deficiencies or feed quality problems reduces susceptibility to infection. Clean, fresh water must always be available, as dehydration increases vulnerability to disease. Feed storage and handling should prevent contamination and maintain nutritional quality.

Monitoring and testing programs allow early detection of mycoplasma and inform management decisions. Regular serological testing of representative flock samples identifies seroconversion indicating exposure. ELISA testing provides quantitative results useful for monitoring antibody levels over time. PCR testing of tracheal swabs detects active infection regardless of antibody status. Testing before introducing new birds and before breeding helps prevent transmission. The National Poultry Improvement Plan (NPIP) in the United States provides standardized testing protocols and certification for mycoplasma-free status.

Vaccination can reduce clinical disease from mycoplasma infection in some situations, though vaccines do not prevent infection or eliminate the carrier state. Live attenuated vaccines for MG are available and can be administered by spray, eyedrop, or drinking water. These vaccines establish a mild infection that stimulates immunity without causing severe disease. Killed bacterin vaccines require injection but do not establish infection. Vaccine use is generally reserved for situations where MG is endemic and elimination is not practical. MS vaccines are less widely used. Vaccination programs should be developed in consultation with poultry veterinarians based on specific flock circumstances.

Daily management of flocks living with mycoplasma infection requires consistent attention to minimizing stress and preventing disease flares. Regular observation of bird behavior and respiratory signs helps detect problems early. Feed and water consumption should be monitored as indicators of flock health. Environmental conditions including temperature, ventilation, and litter quality should be checked and optimized daily. Stressful events such as vaccination, handling, or management changes should be minimized or carefully managed when unavoidable. Maintaining consistent routines reduces stress that could trigger disease recurrence.

Environmental modifications help reduce disease expression in mycoplasma-positive flocks. Ventilation systems should maintain excellent air quality while avoiding drafts that stress birds. Ammonia levels should be kept below detectable limits through proper litter management and ventilation. Temperature should be maintained within the comfort zone for the species and age of birds. Humidity levels should be moderate to prevent respiratory irritation from either excessively dry or damp conditions. Reducing stocking density gives birds more space and reduces transmission opportunities.

Quality of life considerations remain important even in flocks managed as positive for mycoplasma. Birds should be able to engage in normal behaviors including foraging, dust bathing, perching, and social interaction. Environmental enrichment helps maintain behavioral health and reduce stress. Birds with chronic lameness from MS-associated joint damage may need accommodations such as lowered perches or additional resting areas. Individual birds that cannot maintain acceptable quality of life should be humanely euthanized rather than allowed to suffer from chronic disease.

Ongoing monitoring and veterinary care help manage mycoplasma-positive flocks effectively over time. Regular serological monitoring tracks antibody levels and can indicate changes in disease activity. Clinical assessments should note any changes in respiratory signs or lameness. Mortality and culling records help identify trends that may indicate deteriorating flock health. Production records for laying flocks show the ongoing impact of infection on egg production. Periodic veterinary consultation allows review of management strategies and adjustment based on flock performance.

Caregiver resources for managing mycoplasma-positive flocks include educational materials, diagnostic laboratory support, and professional veterinary guidance. Understanding the biology and epidemiology of mycoplasma helps caregivers make informed management decisions. Diagnostic laboratories can perform testing to monitor flock status and identify other concurrent diseases. Poultry extension specialists may provide additional guidance specific to local conditions. Online communities and poultry organizations offer peer support and shared experiences. Accepting that complete elimination may not be practical in some situations allows focus on managing the condition effectively rather than pursuing unattainable goals.

Chickens and turkeys are the primary poultry species affected by the major mycoplasma pathogens MG and MS. In chickens, both layer and meat-type birds are susceptible, with disease expression influenced by genetic background, immune status, and environmental conditions. Commercial layers often experience significant production impacts from MG infection. Broilers may show subclinical infection or develop airsacculitis that leads to processing condemnation. Turkeys are particularly susceptible to severe MG infection, with infectious sinusitis causing dramatic facial swelling and significant economic losses. MS affects both chickens and turkeys, though disease patterns differ somewhat between species.

Other domestic and wild bird species can harbor mycoplasma, creating potential reservoirs for transmission to poultry. Game birds including pheasants, quail, and partridge can be infected with poultry mycoplasmas. Domestic ducks and geese are generally resistant to MG and MS but may carry other mycoplasma species. Pigeons have their own mycoplasma species but are not typically significant in poultry disease epidemiology. Wild birds, particularly house finches and other passerines, can carry MG strains that may occasionally transmit to poultry. Managing wild bird access to poultry facilities helps reduce this risk.

Testing recommendations for mycoplasma focus on screening breeding stock and monitoring commercial flocks. The National Poultry Improvement Plan (NPIP) provides standardized protocols for testing breeding flocks and certifying mycoplasma-free status. Primary breeding companies maintain rigorous testing programs to ensure clean foundation stock. Multiplier and commercial breeder flocks should be tested regularly to confirm continued negative status. Commercial layer and broiler flocks may be monitored for evidence of field infection. Backyard flock owners should consider testing before purchasing birds and periodically thereafter, particularly if respiratory disease occurs. Serological screening provides efficient initial assessment, with positive results confirmed through PCR or culture when necessary.

Mycoplasma infections frequently occur concurrently with other respiratory diseases, creating complex disease syndromes that are more severe than any single infection alone. Viral respiratory diseases including Newcastle disease, infectious bronchitis, and infectious laryngotracheitis dramatically increase the severity of mycoplasma disease when present together. Secondary bacterial infections with Escherichia coli, Ornithobacterium rhinotracheale, or Pasteurella multocida commonly complicate mycoplasma respiratory disease. This interplay of multiple pathogens, sometimes called the respiratory disease complex, makes diagnosis and treatment more challenging and outcomes less predictable.

Several conditions produce clinical signs similar to mycoplasma infection and require differentiation. Infectious coryza caused by Avibacterium paragallinarum produces facial swelling and nasal discharge resembling MG infection but typically has more acute onset and responds to different antibiotics. Ornithobacterium rhinotracheale causes respiratory disease that may be clinically indistinguishable from mycoplasma without laboratory testing. Aspergillosis can cause chronic respiratory disease, particularly in immunocompromised birds. Nutritional deficiencies affecting vitamin A can predispose to respiratory problems that may be confused with infectious disease. Viral arthritis from reovirus causes joint swelling similar to MS synovitis. Accurate diagnosis through appropriate laboratory testing guides effective treatment.

Complications of mycoplasma infection extend beyond the primary respiratory and joint manifestations. Chronic infection leads to persistent immunosuppression that increases vulnerability to other diseases. Vaccine responses may be impaired in mycoplasma-infected birds. Airsacculitis causes processing condemnation losses in broiler chickens. Egg transmission perpetuates infection across generations, complicating eradication efforts. Poor hatchability and chick quality occur when infected breeders transmit mycoplasma to offspring. Recognizing these potential complications informs comprehensive management strategies that address both immediate disease and long-term flock health.